Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line

Pharmacological Reports

Volumn 66, Issue 1, 2014, Pages 121-129

  Sławińska Brych, Adrianna ^a   Zdzisińska, Barbara ^a   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Actin cytoskeleton; Fluvastatin; Glioma cells; MAPKs; MMP 9; VEGF

Indexed keywords

FLUINDOSTATIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; VASCULOTROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MONOUNSATURATED FATTY ACID; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN A;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRDU ASSAY; CANCER INHIBITION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GLIOMA CELL; METASTASIS INHIBITION; MTT ASSAY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING; WOUND HEALING ASSAY; ANIMAL; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL MOTION; DRUG EFFECTS; GLIOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOSKELETON; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS, MONOUNSATURATED; GLIOMA; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 9; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899631400     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.01.002     Document Type: Article

References (49)

1. Agarwal B, Halmos B, Feoktisov AS, Protiva P, Ramey WG, Chen M, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Car-cinogenesis 2002;23:521-8 (Pubitemid 34257633)
2. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis Faith G, Il'yasova D, et al. Brain tumor epidemiology: consensus from the brain tumor epidemi-ology consortium (BTEC). Cancer 2008;113:1953-68
3. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibi-tion of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 2000;20:2761-71 (Pubitemid 30614496)
4. Cerezo-Guisado MI, Alvarez-Barrientos A, Argent R, Garcá- Maŕn LJ, Bragado MJ, Lorenzo MJ. c-Jun N-terminal protein kinase signalling pathway mediates lovastatin-induced rat brain neuroblast apoptosis. Biochim Biophys Acta 2007;1771:164-76 (Pubitemid 46210186)
5. Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006;18:32-9
6. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001;187: 81-9 (Pubitemid 32611661)
7. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70:217-28 (Pubitemid 39545733)
8. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, et al. Molecular mechanism of the anti-cancer activity of crivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003;15: 327-38 (Pubitemid 36071677)
9. Denoyelle C, Vasse M, Kö rner M, Mishal Z, Ganné F, Vannier JP, et al. Cer-ivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48 (Pubitemid 32737327)
10. Feleszko W, Bakowiec EZ, Sieberth M, Marczak A, Dabrowska A, Giermasz A, et al. Lovastatin and TNF-a demonstrate potentiated antitumor effects against Ha-ras transformed murine tumor via inhibition of tumor-induced angiogen-esis. Int J Cancer 1999;81:560-7 (Pubitemid 29203053)
11. Feleszko W, Mynarczuk I, Nowis D. Correspondence in vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. FEBS Lett 2001;503:219-20 (Pubitemid 32763209)
12. Forsyth PA, Laing TD, Gibson AW, Rewcastle NB, Brasher P, Sutherland G, et al. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol 1998;36:21-9 (Pubitemid 28230649)
13. Girgert R, Vogt Y, Becke D, Bruchelt G, Schweizer P. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. Cancer Lett 1999;137:167-72 (Pubitemid 29179460)
14. Graaf MR, Richel DJ, Van Noorden CJF, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609-41 (Pubitemid 39451828)
15. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000;97:6242-4 (Pubitemid 30412695)
16. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle specific effects of lovastatin. Proc Natl Acad Sci U S A 1991;88:3628-32 (Pubitemid 21916676)
17. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM. Lovastatin-induced up-regulation of the BH3-only protein Bim, and cell death in glioblastoma cells. J Neurochem 2004;89:168-78 (Pubitemid 38420686)
18. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003;170:237-43 (Pubitemid 37377795)
19. Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep 2009;21:1317-22
20. Kargiotis O, Rao JO, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol 2006;78:281-93 (Pubitemid 44018823)
21. Khaidakov M, Wang W, Khan JA, Kang BY, Hermonat PL, Mehta JL Statins and Angiogenesis: Is It about Connections? Biochem Biophys Res Commun 2009;387:543-7
22. Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signaling through JNK. Cancer Lett 2007;250:220-8 (Pubitemid 46529446)
23. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-75 (Pubitemid 36566165)
24. Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 1999;42:1-11 (Pubitemid 29216785)
25. Maksimova E, Yie TA, Rom WN. In vitro mechanism of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 2008;186:45-54
26. Menge T, Hartung HP, Stü ve O
27. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-60
28. Obara S, Nakata M, Takeshima H, Kuratsu J, Maruyama, Kitajima I. Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK). Cancer Lett 2002;185:153-61
29. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108 (Pubitemid 40287792)
30. Otsuki T, Sakaguchi H, Hatayama T, Fujii T, Tsujioka T, Sugihara T, et al. Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells. Oncol Rep 2004;11:1053-8
31. Plate KH, Breiner G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993;53
32. Pooler AM, Xi SJC, Wurtman RJ. The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal. J Neuroch 2006;97:716-23
33. Randy L, Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998;49:189-96 (Pubitemid 28068425)
34. Rzeski W, Kocki T, Dybel A, Wejksza K, Zdzisiníska B, Kandefer-SzerszeníM, et al. Demonstration of kynurenine aminotransferases I and II and characteri-zation of kynurenic acid synthesis in cultured cerebral cortical neurons. J Neurosci Res 2005;80:677-82 (Pubitemid 40896188)
35. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67:4524-32 (Pubitemid 46815104)
36. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44 (Pubitemid 29144487)
37. Shibata T, Tamura M, Kabashima N, Serino R, Tokunaga M, Matsumoto M, et al. Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. Life Sci 2009;84: 725-31
38. Sawiníska A, Kandefer-SzerszeníM, Sotwiníska M, Tustanowska A, Śniez ko R. The mechanism of the anticancer activity of statins. Folia Histochem Cytobiol 2005;43:69
39. Sutter AP, Maaser K, Hö pfner M, Huether A, Schuppan D, Scherü bl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005;43:808-16
40. Takenaka M, Hirade K, Tanabe K, Akamatsu S, Dohi S, Matsuno H, et al. Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 2003;301: 198-203 (Pubitemid 36268867)
41. Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, et al. Blocade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-b as angiogenic factors in mouse osteosarcoma. Cytokine 2011;54:100-7
42. van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Brogers-Boer L, van de Donk NW. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2009;33:100-8
43. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through activation of caspase-3 and DNA II in leukemia HL-60 cells. Pharmacol Toxicol 2000;86:83-91
44. Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011;12: 495-508
45. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95-112 (Pubitemid 36694752)
46. Wong W, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibi-tors and malignant cells: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19 (Pubitemid 34460459)
47. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;15:6461-8 (Pubitemid 39297901)
48. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et al. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Canc Res 2011;30:74
49. Zhang S, Wang XL, Gan YH, Li SL. Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcino-ma cells. Anticancer Drugs 2010,678-86.